MAPT and Alzheimer disease: As these biological pathways can modulate tau kinase or phosphatase activity, we deemed that alterations in these pathways would likely affect the equilibrium in the phosphorylation status of Tau34–37 and that putatively pathogenic somatic mutations in HIF of AD could be associated with dysregulation of tau phosphorylation.